• Sabutoclax and the Future of Apoptosis-Based Cancer Thera...

  2025-10-23

  Translational oncology faces persistent challenges in overcoming resistance to apoptosis in cancer cells. Sabutoclax, a potent pan-Bcl-2 family inhibitor, has emerged as a next-generation tool for both mechanistic studies and preclinical development, targeting multiple anti-apoptotic proteins. This thought-leadership article explores the biological rationale of Bcl-2 protein inhibition, details experimental best practices for evaluating apoptosis in vitro, surveys the evolving competitive landscape, and provides strategic guidance for translational researchers aiming to accelerate apoptosis-targeted cancer therapies.

• Nonivamide: A TRPV1 Receptor Agonist Transforming Cancer ...

  2025-10-22

  Nonivamide, a capsaicin analog and selective TRPV1 receptor agonist, is redefining anti-proliferative strategies in cancer research by enabling precise mitochondrial apoptosis induction and robust neuroimmune modulation. This article details optimized experimental workflows, advanced applications in glioma and SCLC models, and practical troubleshooting tips for maximizing outcomes with Nonivamide.

• CA-074 Me: Unraveling Cathepsin B Inhibition in Necroptos...

  2025-10-21

  Explore how CA-074 Me, a potent cathepsin B inhibitor, enables advanced dissection of necroptosis and lysosomal protease signaling. This in-depth analysis connects recent mechanistic discoveries with innovative experimental strategies, offering fresh insights for apoptosis and inflammation research.

168 records 12/12 page Previous First page 上5页 1112